Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check6 days agoChange DetectedIntroducing a major operational notice about funding status and updated versioning to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference4%
- Check14 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new software version.SummaryDifference0.1%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedUpdate to v3.0.2 replacing v3.0.1; removal of the 'Back to Top' link; no other substantive changes.SummaryDifference0.2%
- Check36 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and specific location details in Beijing, while several related terms and categories have been removed, including various medical classifications and the previous version number.SummaryDifference3%
- Check58 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%
Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.